Management of metastatic renal cell carcinoma in the era of targeted therapies

Internal Medicine Journal

Volumn 41, Issue 8, 2011, Pages 594-605

  Webber, Kate ^a,b   Cooper, A ^d   Kleiven, H ^d   Yip, D ^d,e   Goldstein, D ^a,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d CANBERRA HOSPITAL   (Australia)

^e The Australian National University   (Australia)

Author keywords

Carcinoma; Renal; Retrospective; Survival

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; PAZOPANIB; SORAFENIB; TEMSIROLIMUS;

ADULT; AGED; ANOREXIA; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; DIARRHEA; DRUG TARGETING; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; FATIGUE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80051593067     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02540.x     Document Type: Review

References (42)

1. AIHW (Australian Institute of Health and Welfare), AACR (Australasian Association of Cancer Registries). Cancer in Australia: An Overview, 2008. Cancer series no. 46. Cat. no. CAN 42. Canberra: AIHW; 2008.
2. Stavrou E, Baker D, Bishop J. Kidney Cancer in New South Wales. Sydney: Cancer Institute NSW; 2009.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-32.
5. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 2163-72.
6. Lonser RR, Glenn GM, Walther MC, Chew EY, Libutti SK, Linehan WM etal. von Hippel-Lindau disease. Lancet 2003; 361: 2059-67.
7. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L etal. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-43.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud M, Bracarda S, Szczylik C etal. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
10. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S etal. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-50.
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115.
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M etal. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-18.
15. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J etal. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8.
16. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes G, Bolte O etal. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: 975-84.
17. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J etal. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4462-8.
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271.
19. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
20. Hutson TE, Davis ID, Machiels J-PH, De Souza PL, Rottey S, Honh BF etal. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 28: 475-80.
21. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S etal. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63.
22. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). DCTD, NCI, NIH, DHHS. 2006. [Cited 2010 Apr 3]. Available from URL.
23. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289.
24. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C etal. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9.
25. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST etal. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Acta Oncol 2011; 22: 295-300.
26. Read J, Choy STB, Beale P, Clarke S. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 2006; 55: 78-85.
27. Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 2009; 250: 268-72.
28. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005; 92: 1834-6.
29. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW etal. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-66.
30. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM etal. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2008; 27: 235-41.
31. Keegan KA, Hellenthal NJ, Chamie K, Koppie TM. Histopathology in surgically treated renal cell carcinoma: is there a survival difference when stratified by stage? J Clin Oncol 2009; 27 (Suppl): abstr 5089.
32. Bono P, Elfving H, Utriainen T, Österlund P, Saarto T, Alanko T etal. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009; 20: 393.
33. Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011; 50: 569-73.
34. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117.
35. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009; 20: 966-7.
36. Pal SK, Kortylewski M, Yu H, Figlin RA. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther 2010; 9: 3115-25.
37. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA etal. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56: 1131.
38. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ etal. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.
39. Langenberg MHG, van Herpen CML, De Bono J, Schellens JHM, Unger C, Hoekman K etal. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27: 6152-9.
40. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C etal. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-12.
41. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-48.
42. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J etal. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-11.